Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
A physician sending off a quick update to a patient via smartphone; a medical caretaker receiving an alert message that a patient’s medical device requires immediate attention. These are no…
While assessing patient perspectives in comprehensive drug and treatment analyses may sound like a contemporary issue, the Mapi Group has been a pioneer in the practice for over forty years.…
Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of…
GEODIS MD Stéphanie Hervé speaks about the company’s consolidated pharmaceutical logistics market with the 2011 acquisition of pre-wholesaler Pharmalog as well as the recent acquisition of OHL in the United…
Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of…
Pharmaceuticals do not appear in pharmacies and hospitals out of nowhere, yet the logistics of transporting these goods are a seldom acknowledged component of the healthcare industry supply chain. Behind…
PwC France’s pharma and life sciences industry leader speaks out about the consultancy’s positioning as partner of choice for advisory services in the pharmaceutical industry with more than 75 percent…
Sebastien Aguettant, president of the French Association of Pharmaceutical Contract Manufacturers (SPIS) and president of leading French CMO Delpharm, discusses the evolutions and growing significance of contract manufacturing, how CMO…
Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product:…
Thépenier CEO Tsuyoshi Hasuo has imparted a unique vision to internationalize the Normandy-based French company encompassing a company turnaround and a maximization of growth potential. Together with Deputy CEO, Bertrand…
Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the…
Growing awareness of start-up activity within France, fuelled by Minister for the Economy, Industry and Digital Affairs Emmanuel Macron’s ‘La French Tech program,’ is finally helping to place French start-ups…
See our Cookie Privacy Policy Here
